# Papilledema and Pseudopapilledema in Alagille Syndrome: A Case Report

**Authors:** Muhammad A Khan, Danica Joseph, Chamil Dayajeewa, Timothy Ang, Krishna Tumuluri, Kate Reid

PMC · DOI: 10.1080/01658107.2025.2495293 · Neuro-Ophthalmology · 2025-05-21

## TL;DR

This case report describes a rare instance of optic disc swelling in a patient with Alagille syndrome, highlighting the challenges of distinguishing between pseudopapilledema and true papilledema.

## Contribution

The paper presents a unique case where both pseudopapilledema and true papilledema coexist in Alagille syndrome, emphasizing the need for accurate diagnosis.

## Key findings

- Bilateral optic nerve sheath fenestration reversed new visual field loss in the patient.
- Pseudopapilledema from ALGS glial proliferation and true papilledema co-existed in the patient.
- Systemic comorbidities in ALGS require coordinated multidisciplinary care for managing papilledema.

## Abstract

Alagille syndrome (ALGS) is a rare, multisystem, autosomal dominant disorder of variable penetrance, typically dominated by the consequences of bile duct paucity and congenital heart disease. Neuro-ophthalmic findings include optic disc swelling and cerebral vascular anomalies. Here, we discuss the care of a lean young man with ALGS and extreme optic disc swelling. He had significant systemic co-morbidities, in the form of renal failure and anticoagulation after cardiac surgery. His disc swelling proved to be due to a combination of pseudopapilledema from ALGS glial proliferation with possible drusen, and true papilledema, with cerebrospinal fluid (CSF) opening pressure of 31 cm H2O at lumbar puncture.

Despite renally adjusted acetazolamide and topiramate, field loss beyond blind spot enlargement emerged. CSF shunting was deemed unwise, due to the high revision rate which so often follows. Bilateral optic nerve sheath fenestration was therefore undertaken, and succeeded in reversing the new field loss. Disc swelling did not decline dramatically, due to the ALGS pseudopapilledema as well as the presumed chronicity of the patient’s papilledema.

Since pseudopapilledema and papilledema can co-exist in ALGS, it is important to adequately distinguish them, ensuring that the emerging visual threat from true papilledema is not overlooked. Systemic comorbidities of the syndrome will need thoughtful care from a co-ordinated multidisciplinary team when treating the papilledema. Screening for cerebral aneurysm is another important principle in the care of patients with ALGS.

## Linked entities

- **Chemicals:** acetazolamide (PubChem CID 1986), topiramate (PubChem CID 5284627)
- **Diseases:** Alagille syndrome (MONDO:0007318), renal failure (MONDO:0001106)

## Full-text entities

- **Diseases:** Pseudopapilledema (MESH:C562401), ALGS (MESH:D016738), drusen (MESH:D015593), congenital heart disease (MESH:D006330), cerebral aneurysm (MESH:D002532), renal failure (MESH:D051437), autosomal dominant disorder (MESH:D030342), Disc swelling (MESH:D010211)
- **Chemicals:** acetazolamide (MESH:D000086), topiramate (MESH:D000077236), H2O (MESH:D014867)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12990938/full.md

## Figures

12 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12990938/full.md

## References

12 references — full list in the complete paper: https://tomesphere.com/paper/PMC12990938/full.md

---
Source: https://tomesphere.com/paper/PMC12990938